**Chapter 6**

*Human Papillomavirus*

[27] Romanowski B. Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines. Human

study. Papillomavirus Research.

[35] Connelly LB, Le HN. Costeffectiveness of a bivalent human papillomavirus vaccination program in Japan. Sexual Health.

[36] Annemans L, Rémy V, Oyee J, Largeron N. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. PharmacoEconomics.

[37] Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: A review of the cost-effectiveness of vaccination against oncogenic HPV types. Journal of Managed Care Pharmacy.

2018;**5**:96-103

2015;**12**(6):520-531

2009;**27**(3):231-245

2010;**16**(3):217-230

Vaccines. 2011;**7**(2):161-169

2013;**9**(7):1399-1406

2018;**148**(1):3-4

2018;**45**(4):260-265

[28] Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: Results from the Costa Rica Vaccine Trial. Human Vaccines & Immunotherapeutics.

[29] Dilley S, Miller K, Huh W. HPV vaccination. Gynecologic Oncology.

[30] Saccucci M, Franco EL, Ding L, Bernstein DI, Brown D, Kahn JA. Nonvaccine-type human papillomavirus prevalence after vaccine introduction: No evidence for type replacement but evidence for cross-protection. Sexually Transmitted Diseases.

[31] Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proceedings of the National Academy of Sciences of the United States of America. 1992;**89**(24):12180-12184

[32] Principi N, Esposito S. Aluminum in vaccines: Does it create a safety problem? Vaccine.

[33] Little DT, Ward HR. Ongoing inadequacy of quadrivalent HPV vaccine safety studies. BMJ Evidence-Based Medicine. 7 Jan 2019; pii:

[34] Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: Results of the Nagoya

2018;**36**(39):5825-5831

bmjebm-2018-111122

**104**
